Cytokine patterns and survival in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 25, Issue 4, 2010, Pages 1239-1243

  Cohen, Scott D ^a   Phillips, Terry M ^c   Khetpal, Prashant ^a   Kimmel, Paul L ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Cytokines; ESRD; Factor analysis; Survival

Indexed keywords

CYTOKINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CELL COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FACTORIAL ANALYSIS; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL; T LYMPHOCYTE;

CYTOKINES; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950277183     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp625     Document Type: Article

References (26)

1. Foley RN, Collins AJ. End stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-2648
2. Lowrie EG, Lew NL. Death risk in haemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 25: 458-482
3. Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in haemodialysis patients. Am J Kidney Dis 2000; 35: 469-476
4. Menon V, Greene T, Wang X, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766-772
5. Panichi V, Maggiore U, Taccola D, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1154-1160
6. Tripepi G, Mallamaci F, Zoccali C. Inflammation markers, adhesion molecules, and all-cause and cardiovascular mortality in patients with ESRD: searching for the best risk marker by multivariate modeling. J Am Soc Nephrol 2005; 16: S83-S88
7. Owen WF Jr, Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing haemodialysis. N Engl J Med 1993; 329: 1001-1006
8. Hakim RM, Breyer J, Ismail N, et al. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis 1994; 23: 661-669
9. Girndt M, Kohler H, Schiedheim-Weick E, et al. Production of inter-leukin-6, tumor necrosis factor-alpha, and interleukin-10 in vitro correlates with the clinical immune defect in chronic haemodialysis patients. Kidney Int 1995; 47: 559-565
10. Kay NE, Raij LR. Immune abnormalities in renal failure and haemo-dialysis. Blood Purif 1986; 4: 120-129
11. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflamma-tory index correlates with poor outcome in haemodialysis patients. Kidney Int 2007; 72: 1149-1156
12. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and survival in haemodialysis patients. Kidney Int 1998; 54: 236-244
13. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-459
14. Varela MP, Kimmel PL, Phillips TM, et al. Biocompatibility of hae-modialysis membranes: interrelations between plasma complement and cytokine levels. Blood Purif 2001; 19: 370-379
15. Frank RD, Weber J, Dresbach H, et al. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 2001; 60: 1972-1981
16. Horl WH. Haemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13: S62-S71
17. Rao M, Guo D, Perianayagam MC, et al. Plasma interleukin-6 predicts cardiovascular mortality in haemodialysis patients. Am J Kidney Dis 2005; 45: 324-333
18. Chiang CK, Hsu SP, Pai MF, et al. Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2810-2815
19. Plough AL, Schwartz M, Salem SR, et al. Severity analysis in end stage renal disease: a risk group approach. Am Soc Artif Intern Org J 1985; 8: 33-40
20. Le J, Vilcek J. Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. Lab Invest 1987; 56: 234-248
21. Feldman M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest 2008; 118: 3533-3536
22. Zoccali C, Mallamaci F, Tripepi G. Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19: V67-V72
23. Balakrishnan VS, Guo D, Rao M, et al. Cytokine gene polymorphisms in haemodialysis patients: association with comor-bidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449-1460
24. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337
25. Liu Y, Berthier-Schaad Y, Fallin MD, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863-870
26. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hy-poalbuminemia, hypocholesterolemia, and mortality in haemodialysis patients. Am J Kidney Dis 1998; 32: 107-114